Form 4: United Therapeutics CEO Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock on April 28, 2026, under a Rule 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), reported a series of transactions on April 28, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• A total of 9,500 shares were acquired through option exercise at a price of $146.03 per share.
• Following the exercise, 239 shares were sold at a weighted average price of $565.1835, with further sales of 1,598, 1,489, 3,123, 1,531, 926, 228, and 366 shares at various weighted average prices between $566.1432 and $571.7857.
• The total number of shares sold in these transactions amounts to 9,500.
• Following these transactions, Rothblatt beneficially owns 50,013 shares directly and various amounts indirectly through trusts and by spouse.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options or December 31, 2026, whichever comes first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of a significant number of shares by the CEO could be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling and suggests a planned diversification strategy.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less opportunistic trading.
• The exercise of stock options and sale of shares at prices significantly higher than the exercise price ($565.18 to $571.78 vs $146.03) suggests a substantial increase in the stock's value since the options were granted.

Negatives

• A significant number of shares (9,500) were sold by a key executive, which could be interpreted negatively by the market, despite being part of a pre-arranged plan.

Risks

• The Rule 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of a large number of options, introducing a time-bound element to future trading activities.
• The plan's continuation is also contingent on the exercise of 1,734,410 stock options, which expire on March 17, 2027.

Future Outlook

The Rule 10b5-1 trading plan is active until December 31, 2026, or until 1,734,410 stock options are exercised, indicating potential for further transactions within this period.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of trades under a 10b5-1 plan by a CEO is common practice to diversify holdings while adhering to insider trading regulations. The significant difference between the option exercise price and the sale price reflects the company's strong performance in the biotechnology sector.

Stakeholder Impact

• Shareholders: May interpret the CEO's stock sales as a sign of reduced confidence, despite the 10b5-1 plan, potentially impacting short-term share price sentiment.
• Employees: The CEO's stock sales might influence employee morale if perceived as a lack of long-term commitment, though the 10b5-1 plan provides a rationale.
• Management: The transactions align with standard corporate governance practices for executive compensation and diversification.

Next Steps

• The Rule 10b5-1 trading plan will continue until December 31, 2026, or until 1,734,410 stock options are exercised.
• Further transactions may be reported on subsequent Form 4 filings if they occur under the existing plan.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Martine Rothblatt, Stock Options, Insider Trading, 10b5-1 Plan, Beneficial Ownership, Common Stock, Executive Transactions